Clinical Trials Browser

Phase 2 × Interventional × montanide ISA 51 × Clear all

NCT07169617 2026-06-03

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Phase 2 Not yet recruiting

Lung Neoplasms

NCT06202066 2026-05-28

Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas

Phase 2 Recruiting

Adenoma, Islet Cell

NCT02455557 2026-03-30

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma

NCT03003195 2024-09-03

The P10s-PADRE Basket Trial: Vaccination of Metastatic Cancer Patients

Phase 2 Withdrawn

Neoplasm Metastasis, Neoplasms by Site

NCT04013672 2024-08-28

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

Phase 2 Completed

41 enrolled 15 charts

Glioblastoma

NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Phase 2 Completed

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

NCT00020475 2024-03-04

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Phase 2 Completed

Uveal Melanoma, Eye Neoplasms, Neoplasms

NCT00071981 2023-06-28

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Phase 2 Completed

175 enrolled 12 charts

Melanoma

NCT03939234 2022-02-21

Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

Phase 2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00488592 2021-07-12

Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers

Phase 2 Completed

10 enrolled 7 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

Phase 2 Completed

4 enrolled 11 charts

Melanoma, Skin Neoplasms

NCT00089063 2015-04-15

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00001703 2014-07-25

Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma

Phase 2 Terminated

6 enrolled 8 charts

Carcinoma, Renal Cell

NCT00085189 2014-05-22

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00184067 2014-05-21

Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma

Phase 2 Terminated

Melanoma

NCT00303836 2013-06-06

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Phase 2 Terminated

Melanoma

NCT00109811 2013-01-23

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT00001832 2012-12-21

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

Phase 2 Completed

170 enrolled 23 charts

BreastDermatologic

Breast Neoplasms, Melanoma, Neoplasm Metastasis

NCT00059475 2012-10-23

Peptide Vaccination for Patients at High Risk for Recurrent Melanoma

Phase 2 Completed

138 enrolled 16 charts

Melanoma

NCT00273910 2012-10-19

Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma

Phase 2 Completed

104 enrolled 12 charts

Melanoma

NCT00080353 2012-06-14

Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma

Phase 2 Completed

Melanoma